Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133634 | 0.96 | STAT3 (0.42) | STAT3STAT1MAPTHTTHSD17B10 | |
| SCHEMBL7647119 | 0.95 | STAT3 (0.41) | STAT3STAT1MAPTHTTHSD17B10 | |
| SCHEMBL3522373 | 0.95 | STAT3 (0.41) | STAT3STAT1MAPTHTTHSD17B10 | |
| SCHEMBL6003904 | 0.95 | STAT3 (0.41) | STAT3STAT1MAPTHTTHSD17B10 | |
| SCHEMBL15510967 | 0.95 | STAT3 (0.41) | STAT3STAT1MAPTHTTHSD17B10 | |
| SCHEMBL3520094 | 0.95 | STAT3 (0.41) | STAT3STAT1MAPTHTTHSD17B10 | |
| Hydrochloric Acid SCHEMBL27872840 | 0.94 | STAT3 (0.40) | STAT3STAT1MAPTHTTHSD17B10 | |
| SCHEMBL4551743 | 0.93 | STAT3 (0.44) | STAT3STAT1MAPTHTTHSD17B10 | |
| SCHEMBL4944703 | 0.92 | STAT3 (0.40) | STAT3STAT1MAPTHTTHSD17B10 | |
| SCHEMBL17419215 | 0.92 | STAT3 (0.43) | STAT3STAT1MAPTHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718201-B1 | SUBSTITUTED PORPHYRINS | UNIV DUKE (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20150344509-A1 | SUBSTITUTED PORPHYRINS | UNIV DUKE (US) | 2015-12-03 | — | — | US | disclosed |
| US-9096628-B2 | Substituted porphyrins | DUKE UNIVERSITY (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140080797-A1 | SUBSTITUTED PORPHYRINS | DUKE UNIVERSITY (US) | 2014-03-20 | — | — | US | disclosed |
| US-8618089-B2 | Substituted porphyrins | DUKE UNIVERSITY (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120264725-A1 | SUBSTITUTED PORPHYRINS | BATINIC-HABERLE INES (US) | 2012-10-18 | — | — | US | disclosed |
| WO-2012135565-A1 | MOLECULAR CARTESIAN-COORDINATE PLATFORMS | UNIVERSITY OF CHICAGO (US) | 2012-10-04 | — | — | WO | disclosed |
| US-8183364-B2 | Substituted porphyrins | DUKE UNIVERSITY (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100305083-A1 | SUBSTITUTED PORPHYRINS | BATINIC-HABERLE INES | 2010-12-02 | — | — | US | disclosed |
| US-7807825-B2 | Substituted porphyrins | DUKE UNIVERSITY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7485721-B2 | Substituted porphyrins | DUKE UNIVERSITY (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080207582-A1 | Substituted Porphyrins | DUKE UNIVERSITY (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080021007-A1 | Substituted Porphyrins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-01-24 | — | — | US | disclosed |
| EP-1513537-A4 | SUBSTITUTED PORPHYRINS | UNIV DUKE (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1513537-A1 | SUBSTITUTED PORPHYRINS | DUKE UNIVERSITY (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040058902-A1 | Substituted porphyrins | DUKE UNIVERSITY | 2004-03-25 | — | — | US | disclosed |
| WO-2003103680-A1 | SUBSTITUTED PORPHYRINS | DUKE UNIVERSITY (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344509-A1 | SUBSTITUTED PORPHYRINS | PPOX, FECH, MB | STAT3 546/4885STAT1 729/4885MAPT 915/4885 |
| US-20120264725-A1 | SUBSTITUTED PORPHYRINS | PPOX, FECH, MB | STAT3 546/4885STAT1 729/4885MAPT 915/4885 |
| US-20080021007-A1 | Substituted Porphyrins | SOD3, SOD1, PRDX3 | STAT3 4525/4885STAT1 4424/4885MAPT 1837/4885 |
| US-20080207582-A1 | Substituted Porphyrins | SOD3, MPO, SOD1 | STAT3 1497/4885STAT1 1104/4885MAPT 4700/4885 |
| US-20040058902-A1 | Substituted porphyrins | SOD1, SOD3, CAT | STAT3 3010/4885STAT1 3134/4885MAPT 4506/4885 |
| US-20140080797-A1 | SUBSTITUTED PORPHYRINS | PPOX, FECH, MB | STAT3 546/4885STAT1 729/4885MAPT 915/4885 |
| US-20100305083-A1 | SUBSTITUTED PORPHYRINS | SOD3, SOD1, PRDX3 | STAT3 4527/4885STAT1 4415/4885MAPT 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.